Sec Form 3 Filing - Kowalsky Matthew Paul @ Sigilon Therapeutics, Inc. - 2023-02-28

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Kowalsky Matthew Paul 2. Issuer Name and Ticker or Trading Symbol Sigilon Therapeutics, Inc. [ SGTX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) CHIEF OF STAFF AND CLO (Last) (First) (Middle) C/O SIGILON THERAPEUTICS, INC., 100 BINNEY STREET STE 600 3. Date of Earliest Transaction (MM/DD/YY) 02/28/2023 (Street) CAMBRIDGE, MA02142 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 19,683 ( 1 ) D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (Right to Buy) $ 4.12 ( 2 ) 06/05/2029 Common Stock 77,777 D Stock Option (Right to Buy) $ 9.39 ( 3 ) 02/26/2030 Common Stock 1,110 D Stock Option (Right to Buy) $ 39.81 ( 4 ) 02/10/2031 Common Stock 50,000 D Stock Option (Right to Buy) $ 3.03 ( 5 ) 01/02/2032 Common Stock 90,000 D Stock Option (Right to Buy) $ 1.48 ( 6 ) 02/17/2032 Common Stock 105,000 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Kowalsky Matthew Paul C/O SIGILON THERAPEUTICS, INC. 100 BINNEY STREET STE 600 CAMBRIDGE, MA02142 CHIEF OF STAFF AND CLO Signatures /s/ Matthew Kowalsky 02/28/2023 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Includes 10,000 restricted stock units that vest as to 25% on October 29, 2023, which is the second anniversary of the date of grant, and 75% on the third anniversary of the date of grant, subject to the grantee's continued service to the Company on each vesting date. ( 2 )The option vested as to 25% of the underlying shares of common stock on May 6, 2020, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested. ( 3 )The option vested as to 50% of the underlying shares of common stock on October 23, 2020, based on the Company's satisfaction of certain performance criteria. The option vested as to 50% of the underlying shares of common stock on October 23, 2021, the first anniversary of the vesting commencement date. ( 4 )The option vested as to 25% of the underlying shares of common stock on February 11, 2022, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested. ( 5 )The option vested as to 30% of the underlying shares of common stock on January 3, 2023, the first anniversary of the vesting commencement date, and 70% on January 3, 2024. ( 6 )The option vested as to 25% of the underlying shares of common stock on February 18, 2023, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.